CLAREMONT, Calif. February 18, 2021 – Synedgen, a biopharma company dedicated to using its Multivalent Innate Immune Signaling Target (MIIST) platform to develop drugs that mimic and enhance the innate immune system, today announced that industry veteran Dennis Fenton, Ph.D., has joined Synedgen’s Board of Directors. Dr. Fenton is a prominent figure in the biotechnology industry and brings more than 30 years of experience in various roles such as operations, manufacturing and partnering.
“We are quite pleased that Dennis has chosen to join Synedgen’s board, given his breadth of experience and relationships in the biotech community and his leadership in successful drug development,” said Shenda Baker, CEO and President of Synedgen. “On behalf of Synedgen’s management and Board, I welcome Dennis and look forward to benefiting from his strategic, operational and clinical knowledge in the years to come.”
“I am excited to be joining Synedgen just as the company contemplates a number of key strategic and development decisions,” said Dr. Dennis Fenton. “During my thirty-plus-year career in biotechnology, I’ve had the opportunity to work with both big and small pharma, and I am particularly impressed by Synedgen’s MIIST platform and the multiple disease areas in which it has been and could be deployed.”
Dennis Fenton, Ph.D., is a member of the board of directors for AnaptysBio, Cirius Therapeutics and Modern Meadow. Previously, Dr. Fenton served on the board of directors of Hospira, Portola Pharmaceuticals, Dendreon, Genzyme, Kythera Biopharmaceuticals, XenoPort, Nora Therapeutics and Amira Pharmaceuticals. Dr. Fenton began his career at Pfizer as a senior researcher before joining Amgen in their first years of operations. Dr. Fenton worked at Amgen for 25 years and held several notable roles, including Executive Vice President, Operations at his retirement in 2008. Dr. Fenton received his Ph.D. in microbiology from Rutgers University.
Synedgen Inc. is a privately held biopharma company that has developed a first-in-class Multivalent Innate Immune Signaling Target (MIIST) therapeutic platform. MIIST therapeutics target mucosal signaling in response to damage to control inflammation, regeneration and infection. Successes from this platform include SNSP113, a Phase 2 drug for Cystic Fibrosis out-licensed to Synspira Therapeutics, Inc. Synedgen’s internal lead asset is MIIST305, a clinic-ready, oral, immunomodulatory drug candidate that repairs GI injury by directing innate mucosal responses to restore GI function and reduce unchecked inflammation and damage. Synedgen is currently developing MIIST305 for the treatment of GI mucositis, a well-defined, acute injury, inflicted on the gastrointestinal tract by radiation and chemotherapeutics during cancer treatment. For more information, please visit www.synedgen.com.
Gilmartin Group, LLC.
619 916 7620